Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
PHARMACEUTICAL PREPARATIONS
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is listed on Nasdaq, where it has traded since January 7, 2022.
- Listed On
- Nasdaq
- Listed Since
- January 7, 2022
- Employees
- 136
- Market Cap
- $3.5B
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 198 institutions reported holding AMLX, with 115.0 million shares worth $2.1 billion in aggregate. The largest reported holder was FMR, with 16.7 million shares worth $300.4 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 16,727,909 | $300M | Added 0.59% |
| BlackRock | 8,827,085 | $159M | Reduced 0.02% |
| Perceptive Advisors | 8,334,882 | $150M | Added 0.6% |
| Tcg Crossover Management | 6,243,812 | $112M | Unchanged |
| Vanguard | 6,051,228 | $109M | Added 4.23% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is AMLX?
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is listed on Nasdaq, where it has traded since January 7, 2022.
Who are the largest institutional holders of AMLX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of AMLX were FMR, BlackRock and Perceptive Advisors.
How many institutions own AMLX?
198 institutions reported a position in AMLX for the quarter ended June 30, 2026, worth $2.1 billion in total.
Did institutions buy or sell AMLX last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for AMLX.
Every reported institutional holder, plus insider and congressional trades in AMLX, on SentiSense.